Web Stats Provided By Google Analytics

Tuesday, February 18, 2014

CytoDyn Submits Protocol to FDA for Phase 2b Clinical Study of PRO...

... of providing ground-breaking advancements in the treatment of HIV.' About PRO 140 PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry inhibitors -- that are intended to protect healthy cells from viral infection. PRO 140 is a ...

http://ift.tt/1jNJbny

No comments:

Post a Comment